IDEAYA Combo Doubles Progression-Free Survival in Uveal Melanoma Trial

Overview

• IDEAYA reported pivotal Phase 2/3 data in metastatic uveal melanoma, a rare eye cancer, showing its darovasertib plus crizotinib regimen beat current care.
• The combination reached a median progression-free survival of 6.9 months versus 3.1 months on standard therapy, a 58% lower risk of disease worsening.
• Tumor responses were higher at 37.1% with the combo versus 5.8% with control, including five complete responses in the combo arm and none in the control group.
• Investigators described a manageable safety profile and saw early signs of a survival benefit, though overall survival data are still immature.
• Following the announcement, IDEAYA shares rose about 26% in premarket trading, according to Benzinga Pro.